These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33011209)

  • 1. Activation of the MAPK pathway (RASopathies) and partial growth hormone insensitivity.
    Malaquias AC; Jorge AAL
    Mol Cell Endocrinol; 2021 Jan; 519():111040. PubMed ID: 33011209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of Growth Failure in Rasopathies.
    Aftab S; Dattani MT
    Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):447-458. PubMed ID: 31115196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical defects resulting in growth hormone insensitivity.
    Wit JM; de Luca F
    Growth Horm IGF Res; 2016 Jun; 28():57-61. PubMed ID: 26670721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RASopathies.
    Rauen KA
    Annu Rev Genomics Hum Genet; 2013; 14():355-69. PubMed ID: 23875798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rasopathies - dysmorphic syndromes with short stature and risk of malignancy.
    Cizmarova M; Kostalova L; Pribilincova Z; Lasabova Z; Hlavata A; Kovacs L; Ilencikova D
    Endocr Regul; 2013 Oct; 47(4):217-22. PubMed ID: 24156711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in RASopathies.
    Aoki Y; Niihori T; Inoue S; Matsubara Y
    J Hum Genet; 2016 Jan; 61(1):33-9. PubMed ID: 26446362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Genetics of Noonan Syndrome and RASopathies.
    Liao J; Mehta L
    Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):435-446. PubMed ID: 31115195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
    Rauen KA; Schoyer L; McCormick F; Lin AE; Allanson JE; Stevenson DA; Gripp KW; Neri G; Carey JC; Legius E; Tartaglia M; Schubbert S; Roberts AE; Gelb BD; Shannon K; Gutmann DH; McMahon M; Guerra C; Fagin JA; Yu B; Aoki Y; Neel BG; Balmain A; Drake RR; Nolan GP; Zenker M; Bollag G; Sebolt-Leopold J; Gibbs JB; Silva AJ; Patton EE; Viskochil DH; Kieran MW; Korf BR; Hagerman RJ; Packer RJ; Melese T
    Am J Med Genet A; 2010 Jan; 152A(1):4-24. PubMed ID: 20014119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noonan syndrome, the Ras-MAPK signalling pathway and short stature.
    Binder G
    Horm Res; 2009 Apr; 71 Suppl 2():64-70. PubMed ID: 19407499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Noonan syndrome can be diagnosed clinically and through molecular genetic analyses].
    Henningsen MK; Jelsig AM; Andersen H; Brusgaard K; Ousager LB; Hertz JM
    Ugeskr Laeger; 2015 Aug; 177(32):V12140755. PubMed ID: 26321587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RASopathies: unraveling mechanisms with animal models.
    Jindal GA; Goyal Y; Burdine RD; Rauen KA; Shvartsman SY
    Dis Model Mech; 2015 Aug; 8(8):769-82. PubMed ID: 26203125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling RASopathies with Genetically Modified Mouse Models.
    Hernández-Porras I; Guerra C
    Methods Mol Biol; 2017; 1487():379-408. PubMed ID: 27924582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RASopathies - what they reveal about RAS/MAPK signaling in skeletal muscle development.
    Rauen KA; Tidyman WE
    Dis Model Mech; 2024 Jun; 17(6):. PubMed ID: 38847227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
    Rauen KA; Schoyer L; Schill L; Stronach B; Albeck J; Andresen BS; Cavé H; Ellis M; Fruchtman SM; Gelb BD; Gibson CC; Gripp K; Hefner E; Huang WYC; Itkin M; Kerr B; Linardic CM; McMahon M; Oberlander B; Perlstein E; Ratner N; Rogers L; Schenck A; Shankar S; Shvartsman S; Stevenson DA; Stites EC; Stork PJS; Sun C; Therrien M; Ullian EM; Widemann BC; Yeh E; Zampino G; Zenker M; Timmer W; McCormick F
    Am J Med Genet A; 2018 Dec; 176(12):2924-2929. PubMed ID: 30302932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Update on the treatment of RASopathies].
    Duat-Rodriguez A; Hernandez-Martin A
    Rev Neurol; 2017 May; 64(s03):S13-S17. PubMed ID: 28524213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic Findings in Noonan and Non-Noonan RASopathies and Patient Eligibility for Growth Hormone Treatment.
    Carcavilla A; Cambra A; Santomé JL; Seidel V; Cruz J; Alonso M; Pozo J; Valenzuela I; Guillén-Navarro E; Santos-Simarro F; González-Casado I; Rodríguez A; Medrano C; López-Siguero JP; Ezquieta B
    J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrinological manifestations in RASopathies.
    Tamburrino F; Scarano E; Schiavariello C; Perri A; Pession A; Mazzanti L
    Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):471-477. PubMed ID: 36401574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copy number variants and rasopathies: germline KRAS duplication in a patient with syndrome including pigmentation abnormalities.
    Gilbert-Dussardier B; Briand-Suleau A; Laurendeau I; Bilan F; Cavé H; Verloes A; Vidaud M; Vidaud D; Pasmant E
    Orphanet J Rare Dis; 2016 Jul; 11(1):101. PubMed ID: 27450488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAS signalling in energy metabolism and rare human diseases.
    Dard L; Bellance N; Lacombe D; Rossignol R
    Biochim Biophys Acta Bioenerg; 2018 Sep; 1859(9):845-867. PubMed ID: 29750912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etiology and Treatment of Growth Delay in Noonan Syndrome.
    Rodríguez F; Gaete X; Cassorla F
    Front Endocrinol (Lausanne); 2021; 12():691240. PubMed ID: 34149626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.